Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab plus induction chemotherapy and sequential concurrent chemoradiotherapy in unresectable stage III NSCLC
ChiCTR2500097379Phase 2Completed
- Sponsor
- Shandong First Medical University
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in non-small cell lung cancer (NSCLC), sponsored by Shandong First Medical University. Primary endpoints: Objective response rate (ORR) and Changes in radiation dosimetry (lung V20 and mean lung dose). Started Feb 2025; status: completed.
02
Drugs
serplulimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500097379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097379.